Emergent BioSolutions will present at the J.P. Morgan Healthcare Conference on January 14, 2026. Audio link available.
Quiver AI Summary
Emergent BioSolutions Inc. announced that CEO Joe Papa will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 5:15 PM PST. An audio link for the live session will be available for 30 days, and presentation slides will be accessible on the company's website. Emergent BioSolutions has a mission to protect and save lives, providing solutions for various health threats, including smallpox, mpox, and opioid overdoses, for over 25 years. For more information, the company encourages visiting its website and following its social media channels.
Potential Positives
- Joe Papa, the CEO, will present at the prestigious J.P. Morgan Healthcare Conference, enhancing the visibility of Emergent BioSolutions in the healthcare sector.
- The presentation provides a platform for Emergent to communicate its strategic initiatives and commitment to public health, potentially attracting investor interest.
- Investors and stakeholders will have access to the company's presentation materials and audio for a month, promoting transparency and engagement.
Potential Negatives
- None
FAQ
What date is Joe Papa's presentation at the J.P. Morgan Healthcare Conference?
Joe Papa's presentation is scheduled for January 14, 2026, at 5:15 PM PST.
Where can I access the audio link for Emergent's conference session?
The audio link for Emergent's session can be accessed through their official website.
How long will the audio link for the presentation be available?
The audio link will be live for up to 30 days following the presentation.
Where can I find the presentation slides?
The presentation slides will be available in the Investors section of the Emergent BioSolutions website during the presentation.
What is the mission of Emergent BioSolutions?
Emergent BioSolutions' mission is to protect and save lives by delivering health solutions for various health threats.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EBS Insider Trading Activity
$EBS insiders have traded $EBS stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:
- COLEEN GLESSNER (EVP, Quality & Ethics, and CPL) sold 30,608 shares for an estimated $306,080
- RONALD RICHARD has made 0 purchases and 2 sales selling 21,984 shares for an estimated $263,077.
- DONALD W DEGOLYER has made 0 purchases and 2 sales selling 25,645 shares for an estimated $255,453.
- SUJATA TYAGI DAYAL sold 8,552 shares for an estimated $85,520
- KATHRYN C ZOON sold 7,086 shares for an estimated $62,852
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$EBS Revenue
$EBS had revenues of $9.1M in Q3 2025. This is a decrease of -9.0% from the same period in the prior year.
You can track EBS financials on Quiver Quantitative's EBS stock page.
$EBS Hedge Fund Activity
We have seen 85 institutional investors add shares of $EBS stock to their portfolio, and 83 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 705,004 shares (+40.5%) to their portfolio in Q3 2025, for an estimated $6,218,135
- MILLENNIUM MANAGEMENT LLC removed 677,608 shares (-89.7%) from their portfolio in Q3 2025, for an estimated $5,976,502
- AQR CAPITAL MANAGEMENT LLC added 586,246 shares (+inf%) to their portfolio in Q3 2025, for an estimated $5,170,689
- JAIN GLOBAL LLC added 508,707 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,486,795
- PALISADE CAPITAL MANAGEMENT, LP added 326,260 shares (+29.7%) to their portfolio in Q3 2025, for an estimated $2,877,613
- DIMENSIONAL FUND ADVISORS LP added 291,308 shares (+15.8%) to their portfolio in Q3 2025, for an estimated $2,569,336
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 276,566 shares (+25.0%) to their portfolio in Q3 2025, for an estimated $2,439,312
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$EBS Analyst Ratings
Wall Street analysts have issued reports on $EBS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/16/2025
To track analyst ratings and price targets for $EBS, check out Quiver Quantitative's $EBS forecast page.
Full Release
GAITHERSBURG, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that Joe Papa, president and chief executive officer, will provide a company presentation during the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 5:15 PM PST.
The audio link for Emergent’s session may be accessed here and will be live for up to 30 days.
The Company’s slides will be made available at the time of the presentation on the Investors section of the Emergent website.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on
LinkedIn
,
X
,
Instagram
,
Apple Podcasts
and
Spotify
.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
[email protected]
Media Contact:
Assal Hellmer
Vice President, Communications
[email protected]
